Daewon Pharmaceutical Co., Ltd. (KRX:003220)
13,040
-10 (-0.08%)
At close: Oct 24, 2025
Daewon Pharmaceutical Revenue
Daewon Pharmaceutical had revenue of 143.86B KRW in the quarter ending June 30, 2025, with 4.27% growth. This brings the company's revenue in the last twelve months to 603.74B, up 6.68% year-over-year. In the year 2024, Daewon Pharmaceutical had annual revenue of 598.16B with 13.51% growth.
Revenue (ttm)
603.74B
Revenue Growth
+6.68%
P/S Ratio
0.46
Revenue / Employee
470.57M
Employees
1,283
Market Cap
279.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 598.16B | 71.21B | 13.51% |
| Dec 31, 2023 | 526.95B | 48.07B | 10.04% |
| Dec 31, 2022 | 478.88B | 124.71B | 35.21% |
| Dec 31, 2021 | 354.18B | 45.68B | 14.81% |
| Dec 31, 2020 | 308.50B | -9.33B | -2.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |